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In response to viral infection, RIG-I-like RNA heli-
cases bind to viral RNA and activate the mitochon-
drial protein MAVS, which in turn activates the tran-
scription factors IRF3 and NF-kB to induce type I
interferons. We have previously shown that RIG-I
binds to unanchored lysine-63 (K63) polyubiquitin
chains and that this binding is important for MAVS
activation; however, the mechanism underlying
MAVS activation is not understood. Here, we show
that viral infection induces the formation of very large
MAVS aggregates, which potently activate IRF3 in
the cytosol. We find that a fraction of recombinant
MAVS protein forms fibrils that are capable of acti-
vating IRF3. Remarkably, the MAVS fibrils behave
like prions and effectively convert endogenous
MAVS into functional aggregates. We also show
that, in the presence of K63 ubiquitin chains, RIG-I
catalyzes the conversion of MAVS on the mitochon-
drial membrane to prion-like aggregates. These
results suggest that a prion-like conformational
switch of MAVS activates and propagates the anti-
viral signaling cascade.
INTRODUCTION
Innate immunity is an evolutionarily conserved defense mecha-
nism against microbial infections (Iwasaki and Medzhitov,
2010; Ronald and Beutler, 2010; Takeuchi and Akira, 2010). In
higher organisms, an antiviral innate immune response is
triggered by the recognition of viral nucleic acids by germline-
encoded pathogen recognition receptors, including Toll-like
receptors (TLRs) and RIG-I-like receptors (RLRs) (Barbalat
et al., 2011; Rehwinkel and Reis e Sousa, 2010). Several TLRs,
including TLR3, 7, 8, and 9, detect viral RNA and DNA in the
endosome, whereas RLRs bind to viral RNA in the cytoplasm.
Both TLR and RLR pathways activate signaling cascades that
lead to the production of an arsenal of effector molecules that448 Cell 146, 448–461, August 5, 2011 ª2011 Elsevier Inc.suppress viral replication and assembly. Prominent among the
antiviral molecules are type I interferons, including IFNa and
IFNb, which activate the JAK-STAT pathway to fight viral
infection.
RLRs comprise RIG-I, MDA5, and LGP2, all of which contain
anRNA helicase domain (Yoneyama and Fujita, 2009; Yoneyama
et al., 2004). RIG-I also contains a C-terminal regulatory domain
(RD) that binds to viral RNA harboring 50-triphosphate
(50-pppRNA) (Hornung et al., 2006; Pichlmair et al., 2006).
RIG-I and MDA5 detect distinct classes of RNA viruses (Kato
et al., 2006). Both RIG-I and MDA5 contain two CARD domains
in tandem at the N terminus, whereas LGP2 lacks the CARD
domains. The binding of viral RNA to the C termini of RIG-I and
MDA5 presumably induces a conformational change that
exposes the N-terminal CARD domains, which interact with the
CARD domain of the mitochondrial adaptor protein MAVS (also
known as IPS1, VISA, or CARDIF) (Kawai et al., 2005; Meylan
et al., 2005; Seth et al., 2005; Xu et al., 2005). MAVS then
activates the cytosolic kinases IKK and TBK1, which activate
the transcription factors NF-kB and IRF3, respectively. NF-kB
and IRF3 translocate into the nucleus, where they function coop-
eratively to induce type I interferons and other antiviral molecules
(McWhirter et al., 2005).
To understand the mechanism of signal transduction in the
RIG-I pathway, we have recently established a cell-free system
in which viral RNA triggers the activation of IRF3 and IKK in cyto-
solic extracts in the presence of mitochondria (Zeng et al., 2010).
Using this system, we discovered that the CARD domains of
RIG-I bind to unanchored K63 polyubiquitin chains and that
this binding is important for RIG-I activation. The binding of
full-length RIG-I to ubiquitin chains depends on ATP and
50-pppRNA, suggesting that RIG-I activation involves sequential
binding of viral RNA and unanchored K63 polyubiquitin chains to
RIG-I RD and CARDs, respectively. We have also shown that
mitochondria isolated from virus-infected cells can activate IKK
and TBK1 in the cytoplasm and that this activity depends on
MAVS on the mitochondrial membrane (Zeng et al., 2009).
Interestingly, K63 polyubiquitination also plays an important
role in TBK1 activation by MAVS.
The mechanism by which MAVS is activated by RIG-I and
ubiquitin chains is still not understood. The nature of the active
form of MAVS has also remained a mystery. In this report, we
show that MAVS forms very large aggregates after viral infection
and that these aggregates are highly potent in activating IRF3 in
the cytoplasm. Remarkably, these aggregates form self-perpet-
uating fiber-like polymers that can efficiently convert endoge-
nous MAVS into functional aggregates. These properties closely
resemble prions, which are infectious protein conformations
found in pathological as well as physiological conditions (Chien
et al., 2004; Halfmann and Lindquist, 2010; Tuite and Serio,
2010). Initially found to be the causative agent of fatal neurolog-
ical diseases (Prusiner, 1998) —including Scrapies in sheep and
goats, bovine spongiform encephalopathy (BSE, or ‘‘mad cow
disease’’) in cattle, and Creutzfeldt-Jacob disease (CJD) in
human—the prion PrP is the founding member of a growing list
of proteins that can form self-perpetuating aggregates, several
of which have evolved to serve physiological functions. For
example, several prions in fungi regulate phenotypic switches
that may confer selectable advantages (Halfmann and Lindquist,
2010). Thus, the prion-based conformational switch can be
a robust epigenetic mechanism that regulates protein functions
and cellular phenotypes. Properties of prions include fibrous
aggregates, resistance to detergent and protease, and most
importantly, the ability to ‘‘infect’’ the endogenous protein and
convert the native conformation into fibrous aggregates. Strik-
ingly, MAVS possesses all of these prion-like properties. The
formation of MAVS aggregates leads to a gain of function, and
the conformational switch is highly efficient and tightly regulated
by viral infection. Also quite remarkably, in vitro incubation of
RIG-I and mitochondria in the presence of K63 polyubiquitin
chains efficiently converts endogenous MAVS into functional
aggregates.
RESULTS
Viral Infection Induces the Formation of Large MAVS
Signaling Complexes
To understand howMAVS is activated by viral infection, we used
differential centrifugation to isolate crude mitochondria (P5) from
HEK293T cells, which were infected with Sendai virus (+SeV) or
were not infected (SeV). The mitochondrial proteins were ex-
tracted in a buffer containing the nonionic detergent n-dodecyl
beta-D-maltoside (DDM; 1%) and then fractionated by sucrose
gradient ultracentrifugation. Aliquots of the fractions were
analyzed by immunoblotting with a MAVS antibody, whereas
other aliquots were incubated with 35S-IRF3 and HEK293T cyto-
solic extracts in the presence of ATP. The dimerization of IRF3,
which is caused by its phosphorylation by TBK1 and represents
the hallmark of its activation, was measured by native gel elec-
trophoresis (Panne et al., 2007; Yoneyama et al., 2002). As
shown in Figure 1A, viral infection led to the formation of a very
large complex containing MAVS, which activated IRF3 in the
cytosol. This complex was much larger than 26S proteasome
and sedimented toward the bottom of the centrifuge tube con-
taining 50%–60% sucrose. We have previously shown that our
MAVS antibody, which was raised against residues 131–291 of
MAVS, detected two major bands on SDS-PAGE (Seth et al.,
2005). The upper band represents full-length MAVS, whereas
the lower band is a truncated form of MAVS, which lacks the Nterminus but retains the C-terminal transmembrane domain.
Interestingly, only the full-length MAVS formed a large complex
capable of activating IRF3. Furthermore, almost all full-length
MAVS shifted to the large complex in response to viral infection.
To visualize MAVS protein in cells, we expressed YFP-tagged
MAVS inMavs-deficient murine embryonic fibroblasts (MEFs) by
retroviral transduction. Confocal fluorescence microscopy re-
vealed that the staining pattern of YFP-MAVS overlapped with
that of the mitochondrial marker Mitotracker in the absence of
virus infection (Figure 1B). Strikingly, after infection with Sendai
virus, YFP-MAVS appeared to form clusters that partially over-
lapped with Mitotracker, suggesting that MAVS forms aggre-
gates in response to viral infection.
The large size of the active MAVS complex, together with our
previous observation that MAVS in virus-infected cells is more
resistant to detergent extraction (Seth et al., 2005), led us to
test whether MAVS forms detergent-resistant aggregates. We
employed a method called semidenaturing detergent agarose
gel electrophoresis (SDD-AGE), which was previously used for
the detection of prion-like structures (Alberti et al., 2009). In
SDD-AGE, the crude mitochondria (P5) from cells infected with
Sendai virus for different lengths of time were resuspended in
a sample buffer containing 2% SDS and then separated on
1.5% agarose gel by electrophoresis in a running buffer contain-
ing 0.1% SDS (Figure 1C). Strikingly, a smear of SDS-resistant
high-molecular weight MAVS aggregates appeared after 9 hr
of viral infection, much like prions (Alberti et al., 2009). These
aggregates were not detected in cells depleted of MAVS by
RNAi, which blocked IRF3 activation by Sendai virus (Figure S1A
available online). The kinetics of MAVS aggregate formation
correlated with IRF3 activation by mitochondria from the virus-
infected cells (Figure 1C). These results indicate that MAVS
forms very large and highly active signaling complexes following
viral infection.
In Figure 1C, we noted that our MAVS antibody could barely
detect MAVS on SDD-AGE during the early time course of viral
infection but was able to detect MAVS in the same samples
when they were separated by the standard SDS polyacrylamide
gel electrophoresis (SDS-PAGE). A major difference between
SDD-AGE and SDS-PAGE is the presence of a reducing agent
(b-mercaptoethanol or BME) in the latter, but not in the former,
sample buffer. Interestingly, when crude mitochondria were re-
suspended in sample buffers containing different concentrations
of BME followed by SDD-AGE, the smear of high-molecular
weight MAVS aggregates disappeared (Figure 1D). These results
suggest that the SDS-resistant MAVS aggregates may contain
disulfide bonds and that the functional aggregates are preferen-
tially detected by our MAVS antibody.
To determine whether reduction of the MAVS aggregates
alters their activity and/or aggregation, we resuspended mito-
chondria from Sendai virus-infected cells in a buffer containing
1% DDM and 10 mM DTT and then fractionated the mitochon-
drial extracts by sucrose gradient ultracentrifugation. MAVS still
sedimented as very large particles after the DTT treatment, and
these particles were fully capable of activating IRF3 in the cytosol
(Figure S1B). Control experiments showed that the DTT-treated
particles in high-density sucrose fractions no longer formed
detectable MAVS aggregates on SDD-AGE (Figure S1C). Thus,Cell 146, 448–461, August 5, 2011 ª2011 Elsevier Inc. 449
Figure 1. Viral Infection Induces the Formation of Large MAVS Particles that Activate IRF3
(A) Crude mitochondria isolated from HEK293T cells infected with Sendai virus for 14 hr (+SeV) or uninfected (SeV) were solubilized in a buffer containing 1%
DDM and then subjected to sucrose gradient ultracentrifugation. Aliquots of the fractions were immunoblotted with a MAVS antibody or incubated with 35S-IRF3
and cytosolic extracts in the presence of ATP at 30C for 60 min, followed by native gel electrophoresis and autoradiography. Arrows indicate the positions of
proteins used as molecular size markers, including 20S and 26S proteasome. DMAVS denotes a truncated MAVS lacking the N terminus.
(B) YFP-MAVSwas expressed inMavs/MEF cells by retroviral transduction, and the cells expressing low levels of YFP-MAVSwere sorted by FACS. These cells
were infected with Sendai virus for 13 hr, stained with Mitotracker, and then visualized by confocal fluorescent microscopy. The images are representative
of > 50% of the cells under examination.
(C) Crude mitochondrial extracts were prepared from HEK293T cells infected with Sendai virus for the indicated time, and then aliquots of the extracts were
analyzed by SDD-AGE, SDS-PAGE, or IRF3 dimerization assays.
(D) Crude mitochondrial extracts were treated with or without b-mercaptoethanol (BME at 0.35, 3.5, and 35 mM), followed by SDD-AGE.
(E) HEK293T cells were treated with geldanamycin or 17-AAG at the indicated concentrations for 1 hr before Sendai virus infection. Ten hours later, the activation
of endogenous IRF3 in the cytosolic extracts was analyzed by native gel electrophoresis. Mitochondria (P5) were prepared and analyzed by SDD-AGE or
SDS-PAGE using aMAVS antibody. An aliquot of P5 was incubated with cytosolic extracts, 35S-IRF3, and ATP followed by native gel electrophoresis to measure
MAVS activity.
See also Figure S1.DTT treatment prevented the detection of MAVS aggregates
using the SDD-AGE assay but did not cause the breakdown of
the MAVS aggregates, which could be isolated by ultracentrifu-
gation. These MAVS aggregates were still active in causing IRF3450 Cell 146, 448–461, August 5, 2011 ª2011 Elsevier Inc.dimerization (Figure S1B). However, DTT treatment of cells
blocked MAVS aggregation as well as IRF3 activation by Sendai
virus (Figure S1D). This effect was more evident when DTT was
applied during the early time course of virus infection than during
the late time course (Figure S1E). Thus, it is possible that
disulfide bond formation facilitates MAVS aggregation, but the
maintenance of the MAVS aggregates and its activity does not
require the disulfide bonds. In any case, SDD-AGE without
a reducing agent provides a sensitive assay for the detection
of SDS-resistant, functional MAVS aggregates induced by virus
infection.
Previous studies have identified several chemicals that inhibit
IRF3 phosphorylation triggered by RNA viruses and poly[I:C]
(Iwamura et al., 2001). Among these is the Hsp90 inhibitor gelda-
namycin, which inhibits IRF3 phosphorylation through an
unknown mechanism. We found that geldanamycin and its
analog (17-AAG), at concentrations that inhibited IRF3 activa-
tion, also blocked MAVS aggregation induced by Sendai virus
(Figure 1E). Further, mitochondria isolated from cells treated
with the drugs failed to activate IRF3 when incubated with cyto-
solic extracts. In contrast, cytosolic extracts from geldanamycin-
treated cells could still support IRF3 activation when incubated
withmitochondria from virus-infected cells (Figure S1F). Interest-
ingly, the cytosolic extracts fromSendai virus-infected cells were
refractory to activation by mitochondria from virus-infected cells
(Figure S1F, lane 2), suggesting that some signaling proteins in
the cytosol were desensitized following their activation. Taken
together, these results suggest that geldanamycin and 17-AAG
inhibit IRF3 activation by preventing MAVS aggregation on the
mitochondria (see Discussion).
The Active MAVS Complex Is Composed
of MAVS Polymers
To facilitate purification of the active MAVS complex, we gener-
ated a HEK293T cell line stably expressing Flag-MAVS. Analysis
of the mitochondrial extracts from this cell line by sucrose
gradient ultracentrifugation revealed that a fraction of Flag-
MAVS formed a large complex that is capable of activating
IRF3 dimerization even in the absence of viral infection, suggest-
ing that overexpression caused a small fraction of Flag-MAVS to
form the active complex (Figure S2A, top). Sendai virus infection
caused the vast majority of MAVS to form the active complex
(Figure S2A, bottom). However, despite much effort, we were
unable to immunoprecipitate the active MAVS complex with
antibodies against Flag or MAVS under native conditions. We
therefore attempted to carry out immunoprecipitation under
a partially denaturing condition that could maintain the activity
of the MAVS complex. We found that, when the MAVS complex
was solubilized in 2.5M guanidine-HCl and then dialyzed in
a buffer containing 0.5 M guanidine-HCl, it could be immunopre-
cipitated with the Flag antibody, and the dialysis restored its
ability to activate IRF3 (Figure S2B). Based on these experi-
ments, we devised a protocol to purify the functional Flag-
MAVS particles from Sendai virus-infected cells (Figure 2A and
2B). As a control, we also purified Flag-MAVS from uninfected
cells. In both cases, silver staining of the purified particles re-
vealed a predominant band that corresponded to Flag-MAVS
itself (Figure 2B), which was verified by mass spectrometry and
immunoblotting (data not shown). Importantly, only Flag-MAVS
purified from the virus-infected cells formed aggregates and
was capable of activating IRF3 when incubated with cytosolic
extracts (Figure 2C). These results suggest that the activeMAVS particles consist predominantly of theMAVS protein itself,
which likely forms polymers.
Recombinant MAVS Protein Forms Fibrous Polymers
that Activate IRF3
To test directly whether MAVS alone could form functional
polymers, we attempted to express and purify recombinant
MAVS protein in E. coli. Because full-length MAVS containing
the C-terminal transmembrane domain (TM) was largely insol-
uble when expressed in E. coli, we expressed TM-deleted
MAVS (MAVSDTM) in HEK293T cells and then tested its ability
to activate IRF3 in cytosolic extracts (Figures S3A and S3B).
Interestingly, although the TM domain is absolutely required for
MAVS to activate IRF3 and induce IFN in intact cells (Seth
et al., 2005), in vitro incubation of MAVSDTM with cytosolic
extracts led to IRF3 dimerization (Figure S3B, lane 1). This result
suggests that the activity of MAVSDTM is blocked in intact cells
by an unknown mechanism but unleashed in the in vitro assay
(see below). We took advantage of this assay to test a panel of
MAVS deletion mutants and found that the proline-rich region
(residues 103–153) and the C terminus (residues 461–540)
were dispensable for IRF3 activation, whereas the CARD domain
was essential (Figure S3B). Based on these results, we ex-
pressed in E. coli a variant of MAVS lacking TM and proline-
rich region as a fusion protein with Sumo, a ubiquitin-like protein
that is known to facilitate expression of fusion partners in soluble
forms. We purified this protein, termed Sumo-MAVS, to
apparent homogeneity and found that it potently activated
IRF3 in the cytosolic extracts (Figure S3C).
Interestingly, when Sumo-MAVS was analyzed by gel filtration
on Superdex-200, a fraction of the protein eluted in the void
volume, and these high-molecular weight forms activated IRF3
when they were incubated with cytosolic extracts (peak I;
Figure 3A). In contrast, the low-molecular weight forms of
Sumo-MAVS had no activity (peak II). Negative-stain electron
microscopy of the protein particles showed that Sumo-MAVS
in peak I formed large fiber-like polymers, whereas the protein
in peak II formed much smaller particles with globular shapes
(Figure 3B). When Peak II was stored at 4C for 1 or 2 days, it
gradually converted to peak I, indicating that the low-molecular
weight forms of Sumo-MAVS spontaneously formed the fibrous
polymers (Figure S3D). Removal of the Sumo tag caused the
majority of MAVS to elute in peak I, which was also capable of
activating IRF3 (data not shown).We also expressed and purified
mouse MAVS lacking the TM domain as a His6-tagged protein.
The mouse MAVS protein also formed long fibers and were
capable of activating IRF3 in cytosolic extracts (Figure 3C). The
average diameter of the mouse MAVS fibers was smaller than
that of the human Sumo-MAVS fibers, presumably because
the presence of Sumo rendered the fibers thicker. These results
suggest that the ability of MAVS to form fibrous polymers is evo-
lutionally conserved and is independent of the purification tags.
MAVS Fibrils Have a Prion-like Activity that Converts
Endogenous MAVS into Functional Aggregates
A hallmark of prions is their ability to convert endogenous
proteins from their native conformations into prion-like fibrils.
To test whether the MAVS fibrils have the prion-like activity, weCell 146, 448–461, August 5, 2011 ª2011 Elsevier Inc. 451
Figure 2. Purification of Active MAVS
Particles
(A) A protocol for purification of active Flag-MAVS
particles.
(B) Silver staining of Flag-MAVS purified from
HEK293T cells infected with Sendai virus or not
infected.
(C) IRF3 dimerization assay using purified Flag-
MAVS shown in (B). MAVS was also analyzed by
immunoblotting following SDD-AGE and SDS-
PAGE.
See also Figure S2.incubated the peak I and peak II fractions of Sumo-MAVS with
mitochondria from HEK293T cells at room temperature for
30 min and then analyzed endogenous MAVS in the mitochon-
drial extracts by SDD-AGE (Figure 3D). Significantly, MAVS
formed large aggregates after the mitochondria were incubated
with peak I, but not peak II. Even highly diluted peak I (80 ng/ml
Sumo-MAVS; Figure 3D, lane 3), which was not detectable by
the MAVS antibody, caused detectable aggregation of endoge-
nousMAVS, suggesting a catalytic mechanism of this conforma-
tional conversion, which is reminiscent of prion-like infection.
The mitochondria also gained the ability to activate IRF3 after
incubation with peak I, and the activity was detectable with a
concentration of peak I as low as 16 ng/ml (Figure 3E, lane 6).452 Cell 146, 448–461, August 5, 2011 ª2011 Elsevier Inc.In contrast, peak II was unable to activate
the mitochondria even at high concentra-
tions. High concentrations of Peak I alone
modestly activated IRF3, but this activity
was significantly enhanced in the pres-
ence of mitochondria (e.g., compare
lanes 3 and 4 in Figure 3E).
The CARD Domain of MAVS Forms
Protease-Resistant Fibrils with a
Prion-like Activity
Most prions form fiber-like structures that
are resistant to protease digestion (Tuite
and Serio, 2010). To determine whether
the MAVS fibrils are resistant to proteol-
ysis, we fractionated Sumo-MAVS on
Superdex-200 and digested peak I and
peak II with proteinase K (PK). Two prom-
inent PK-resistant fragments appeared
when peak I was digested for 2 hr,
whereas such fragments were much
less visible in the peak II sample (Fig-
ure 4A). The peak II sample contained
a faint band that was relatively resistant
to PK, and this band was identified as
Hsp70 by mass spectrometry (Figure 4A,
lanes 7–10; data not shown). Fraction-
ation of the PK-digested Sumo-MAVS
on Superdex-200 led to the separation
of two peaks, with the first peak eluting
in the void volume, similar to peak I of
undigested Sumo-MAVS (Figure 4B).The second peak from the gel filtration column contained
predominantly Hsp70, as determined by mass spectrometry
(data not shown). Peak I contained a doublet with molecular
weights of 30 kDa. Both bands, designated as PK-MAVS,
were excised for mass spectrometry, which identified multiple
peptides of SUMO and the N terminus of MAVS, but none after
residue 218 of MAVS (Figure S4A). These results suggest that
PK-MAVS contains a fragment from Sumo and the N terminus
of MAVS, including the entire CARD domain (Figure S4B). Nega-
tive-stain electron microscopy of PK-MAVS revealed that it
formed long fibers with an average diameter of 12.6 ± 0.69 nm
and an overall shape similar to that of the prion PrP (Figure 4C
and Figure S4C).
Figure 3. Recombinant MAVS Forms Fiber-like Polymers that Convert Endogenous MAVS into Functional Aggregates
(A) Sumo-MAVS lacking the proline-rich and TM domains was expressed and purified from E. coli, as described in Experimental Procedures, and then further
fractionated by gel filtration on Superdex-200. Each fraction was analyzed by Coomassie blue staining and IRF3 dimerization assay.
(B) Two peaks of the Sumo-MAVS protein, as shown in (A), were imaged by electron microscopy using negative staining.
(C) Mouse MAVS lacking the TM domain was expressed as a His6-tagged protein in E. coli and affinity purified. The purified protein was analyzed by IRF3
dimerization assay and electron microscopy.
(D) Peaks I and II of Sumo-MAVS, as shown in (A), were diluted 5-fold serially as indicated and then incubatedwithmitochondria fromHEK293T cells (total volume:
10 ml). The mitochondria were solubilized in a buffer containing 1% DDM and then analyzed by SDD-AGE and SDS-PAGE with a MAVS antibody.
(E) The mitochondria incubated with Sumo-MAVS as described in (D) were subsequently incubated with 35S-IRF3 and cytosolic extracts to measure IRF3
dimerization.
See also Figure S3.
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Figure 4. MAVS CARD Domain Forms Protease-Resistant Prion-like Fibers that Convert Endogenous MAVS into Functional Aggregates
(A) Sumo-MAVS in peaks I and II from Superdex-200 was digested with proteinase K (PK) for the indicated time at 22C and then analyzed by Coomassie blue
staining.
(B) Sumo-MAVS was treated with or without proteinase K for 1 hr and then fractionated on Superdex-200 (2.4 ml column). The fractions were analyzed by
Coomassie blue staining. Mass spectrometry showed that the protease-resistant fragments in peak I contained the N terminus of MAVS, including the intact
CARD domain (PK-MAVS; Figure S4A), and that the protease-resistant protein in peak II was Hsp70.
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The PK-MAVS fragment was incubated with mitochondria,
which were subsequently analyzed for their ability to activate
IRF3 and form aggregates (Figure 4D). Strikingly, following incu-
bation with even highly diluted PK-MAVS (40–200 ng/ml; lanes 4
and 5), the mitochondria gained the ability to activate IRF3.
Moreover, endogenous MAVS formed large aggregates, as re-
vealed by SDD-AGE. In contrast, neither PrP fibers nor ubiquitin
(as a globular protein control) caused MAVS aggregation or IRF3
activation even at much higher concentrations (Figure 4D, lanes
6–10). PK-MAVS alone did not activate IRF3 even at high
concentrations (Figure 4D, lane 2), indicating that degradation
of the C terminus, which contains binding sites for cytosolic
signaling proteins such as TRAF2, TRAF3, and TRAF6 (Seth
et al., 2005), abrogated its ability to activate IRF3. Thus, the
PK-MAVS fibrils must act through endogenousMAVS to activate
IRF3 in the cytoplasm. In support of this notion, mitochondria
from cells depleted of MAVS by RNAi were unable to support
IRF3 activation by PK-MAVS (Figure S4D). Reconstitution of
MAVS-deficient MEF cells with full-length MAVS, but not
a mutant lacking the CARD domain (MAVS-DCARD), supported
IRF3 activation by PK-MAVS (Figure S4E). Furthermore, sucrose
gradient ultracentrifugation revealed that full-length MAVS, but
not MAVS-DCARD, formed high-molecular weight particles after
the mitochondria were in contact with PK-MAVS (Figure 4E),
indicating that the CARD domain of MAVS on the mitochondrial
surface is required for its conversion to the active form by
PK-MAVS. These results suggest that MAVS activation occurred
through a prion-like conformational switch, which was triggered
and templated by the PK-MAVS fibrils, likely through interaction
between the CARD domains of the ‘‘infectious’’ agent
(PK-MAVS) and that of endogenous MAVS. We estimated that
1 ng of PK-MAVS caused the conversion of 16 ng of endoge-
nous MAVS into functional aggregates within 30 min, again sug-
gesting a prion-like catalytic mechanism.
Because PK-MAVS contains the CARD domain as well as
other sequences (Figure S4A), we tested whether the CARD
domain alone is sufficient to form functional fibrils. We expressed
Flag-MAVS CARD-only (residues 1–100) in HEK293T cells and
purified it to apparent homogeneity (Figure 4F). This protein
alone did not activate IRF3, but its incubation with the mitochon-
dria led to IRF3 activation. Electron microscopy showed that the
CARD domain formed long fibers with an average diameter of
8.39 ± 1.1 nm. This diameter was smaller than that of PK-
MAVS fibers, likely because it did not contain the extra
N-terminal and C-terminal extension sequences found in PK-
MAVS.
Our finding that the CARD domain of MAVS is capable of acti-
vating endogenous MAVS on the mitochondrial membrane(C) The fraction containing PK-MAVS shown in (B) (lane 9) and the prion PrP wer
(D) PK-MAVS and PrP at the indicated amounts were incubated with the mitoch
chondria were subsequently incubated with 35S-IRF3 and cytosolic extracts to m
AGE and SDS-PAGE using a MAVS antibody, which reacts very weakly with PK
(E) TheCARDdomain ofMAVS is required for its conversion into aggregated forms
MEF cells by retroviral transduction. Mitochondria (P5) from these cells were incu
separated by sucrose gradient ultracentrifugation.
(F) The MAVS CARD domain was expressed in HEK293T cells as a Flag fusion pr
IRF3 dimerization assay, and electron microscopy.
See also Figure S4.in vitro is in contrast with our previous reports that the mitochon-
drial localization of MAVS is essential for its function in vivo
(Li et al., 2005; Seth et al., 2005). Consistent with our previous
reports, transfection of Flag-MAVS CARD-only into a HEK293T
IFNb-luciferase reporter cell line failed to induce the luciferase
reporter or IRF3 dimerization (data not shown). When the
MAVS CARD domain was fused to the TM domain, this fusion
protein, termed mini-MAVS, strongly induced IFNb and caused
IRF3 dimerization (Figure S4F). Interestingly, depletion of endog-
enous MAVS by RNAi abrogated IFNb induction by mini-MAVS
(Figure S4F, lanes 5 and 6), indicating that mini-MAVS must
act through endogenous MAVS to induce IFNb. Thus, it ap-
peared that endogenous MAVS on the mitochondria were pre-
vented from being activated by the cytosolic MAVS CARD
domain in intact cells through an unknown mechanism. Intrigu-
ingly, when the MAVS CARD domain is appended to the TM
domain, it is highly potent in activating endogenous MAVS and
IRF3, suggesting that the mitochondrial localization facilitates
MAVS aggregation in cells.
MAVS Aggregates Recruit TRAF2 and TRAF6
Our observation that mini-MAVS requires endogenous MAVS to
induce IFNb suggests that the sequence between the CARD and
TMdomains ofMAVS, which contain binding sites for TRAFs and
other cytosolic signaling proteins, may mediate the recruitment
of these proteins to MAVS aggregates. To test this possibility,
we examined several signaling proteins that are known to be
involved in NF-kB and IRF3 activation by immunoblotting
following sucrose gradient ultracentrifugation of mitochondrial
extracts (Figure 5). Interestingly, TRAF2 and TRAF6, but not
IKKb, TBK1, or IRF3, were found to sediment in the high-molec-
ular weight fractions together with MAVS in response to Sendai
virus infection (Figure 5A). The shifting of TRAF2 and TRAF6 to
the high-molecular weight fractions was abrogated in cells
depleted of MAVS by RNAi (Figure 5B). VDAC1, a mitochondrial
outer-membrane protein, did not comigrate with MAVS after
virus infection, suggesting that virus-induced formation of the
MAVS complex does not lead to nonspecific aggregation of resi-
dent mitochondrial proteins. Further work is needed to under-
stand how the recruitment of TRAF2, TRAF6, and potentially
other signaling proteins to MAVS aggregates lead to the activa-
tion of NF-kB and IRF3.
RIG-I and K63 Polyubiquitin PromoteMAVS Aggregation
on the Mitochondrial Membrane
We have previously shown that RIG-I binds to K63 polyubiquitin
chains through the N-terminal tandem CARD domains and that
this binding is essential for IRF3 activation and interferone imaged by electron microscopy using negative staining.
ondria from HEK293T cells at 22C for 30 min (total volume: 10 ml). The mito-
easure IRF3 dimerization. Mitochondrial extracts were also analyzed by SDD-
-MAVS due to the removal of the epitopes.
by PK-MAVS. Full-lengthMAVS andMAVSDCARDwere expressed inMavs/
bated with or without PK-MAVS for 30 min before mitochondrial proteins were
otein and affinity purified. The purified protein was analyzed by silver staining,
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Figure 5. TRAF2 and TRAF6 Are Recruited
to MAVS Aggregates in Response to Virus
Infection
(A) Crude mitochondria (P5) were isolated from
cells infected with Sendai virus or not infected,
solubilized in 1% DDM, and then separated by
sucrose gradient ultracentrifugation. Fractions
were analyzed by immunoblotting with the indi-
cated antibodies. Aliquots of the fractions were
incubated with cytosolic extracts, 35S-IRF3, and
ATP followed by native gel electrophoresis.
(B) Similar to (A) except that cells were transfected
with siRNA against MAVS or GFP (control) before
virus infection.induction (Zeng et al., 2010). To determine whether RIG-I can
promote MAVS aggregation in vitro, we incubated full-length
RIG-I protein with mitochondria in the presence or absence of
50-pppRNA and ubiquitin chains. Strikingly, after RIG-I was incu-456 Cell 146, 448–461, August 5, 2011 ª2011 Elsevier Inc.bated with 50-pppRNA, ATP, and K63-
Ub4, it caused very rapid formation of
MAVS aggregates on the mitochondrial
membrane (Figure 6A). This activity
required RNA and K63-Ub4 and was not
induced by K48-Ub4 or mono-Ub. Over-
expression of the RIG-I N terminus can
activate IRF3 and induce IFN-b indepen-
dently of viral RNA (Yoneyama et al.,
2004). Purified GST-RIG-I(N) also caused
robust MAVS aggregation when it was
incubated with the mitochondria and
K63-Ub4, but not K48-Ub4 or mono-Ub
(Figure 6B). This activity did not require
ATP and was unaffected by EDTA, which
chelates magnesium (Figure 6B, lanes 10
and 11). The MAVS aggregates were not
observed in cells treated with MAVS
siRNA, confirming the identity of these
aggregates (Figure S5A). Similar to RIG-
I(N), overexpression of MDA5(N) in
HEK293T cells led to aggregation of
endogenous MAVS and dimerization of
IRF3, and mutations of two conserved
residues within the first CARD domain of
MDA5 abrogated its ability to induce
IRF3 dimerization and MAVS aggregation
(Figure S5B). Titration experiments
showed that 60 nM K63-Ub4 (less for
RIG-I[N]:K63-Ub4 complex) was able to
convert 130 nM MAVS into the aggre-
gate forms within 30 min (Figure 6C,
lane 8). Kinetic experiments showed that
MAVS aggregation was evident after
2 min of exposure of the mitochondria to
the RIG-I(N):K63-Ub4 complex (Fig-
ure 6D). SDD-AGE analysis showed that
the SDS-resistant MAVS aggregates
induced by RIG-I(N) and K63-Ub4 weresensitive to DTT treatment (Figure 6E, top); however, DTT treat-
ment did not affect in vitro activation of MAVS by RIG-I(N) and
K63-Ub4 (Figure 6E, bottom). Furthermore, the DTT-reduced
MAVS still sedimented as high-molecular weight particles after
Figure 6. RIG-I and K63-Ub4 Induce MAVS Aggregation and Activation on the Mitochondrial Membrane
(A) Full-length RIG-I was incubated with 50-pppRNA and/or ubiquitin chains as indicated at 22C for 10 min. The mixtures were then incubated with mitochondria
from HEK293T cells for 30 min before mitochondrial extracts were analyzed by SDD-AGE and SDS-PAGE. 0.25 mg of ubiquitin chains or mono-Ub was analyzed
by silver staining (right).
(B) GST-RIG-I(N) was incubated with different ubiquitin chains at 22C for 10 min in the presence or absence of ATP or EDTA as indicated. The mixture was then
incubated with mitochondria from HEK293T cells for the indicated time, followed by analysis of the mitochondrial extracts using SDD-AGE and SDS-PAGE.
(C) Similar to (B) except that varying amounts of GST-RIG-I(N) and K63-Ub4 were used, and their incubation time with mitochondria was kept at 30 min.
(D) GST-RIG-I(N) was incubated with K63-Ub4 and then with mitochondria for the indicated time, followed by analysis of the mitochondrial extracts using
SDD-AGE and SDS-PAGE.
(E) GST-RIG-I(N) was incubated with K63-Ub4 before incubation with mitochondria in the presence or absence of DTT. Themitochondrial extracts were analyzed
by SDD-AGE, SDS-PAGE, and IRF3 dimerization assays. Mitochondria from Sendai virus-infected cells were used as a positive control.
(F) Mitochondrial extracts from (E) were fractionated by sucrose gradient ultracentrifugation followed by SDS-PAGE and immunoblotting with a MAVS antibody.
See also Figure S5.
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Figure 7. A Model of MAVS Activation Involving a Prion-like Conformational Switch Induced by RIG-I
Following sequential binding of RIG-I to viral RNA (50-ppp RNA) and K63 ubiquitin chains, the CARD domains of RIG-I interact with the CARD domain of MAVS.
This interaction induces a conformational change of theMAVSCARD (depicted by the change in color and shape of theCARD), which in turn converts otherMAVS
on the mitochondrial outer membrane into prion-like aggregates. These aggregates activate cytosolic signaling cascades to turn on NF-kB and IRF3, leading to
induction of type I interferons and other antiviral molecules. MAVS on the mitochondrial membrane of uninfected cells may be a multimer but is depicted as
a monomer for simplicity. Also not depicted is the possibility that MAVS on the surface of two adjacent mitochondria could aggregate through the N-terminal
CARD domains, thereby propagating the antiviral signal between mitochondria.sucrose gradient ultracentrifugation (Figure 6F). Thus, the MAVS
aggregates induced in vitro by RIG-I and ubiquitin chains
behaved similarly to those in cells triggered by viral infection.
DISCUSSION
We have previously shown that MAVS becomes more resistant
to extraction with detergent from the mitochondrial membrane
after viral infection (Seth et al., 2005). Recent microscopy studies
show that MAVS redistributes in the mitochondria to form
speckle-like aggregates in cells in response to viral infection
(Onoguchi et al., 2010). In this report, we show that viral infection
induces the formation of very large MAVS aggregates on the
mitochondrial membrane. Importantly, we provide direct
biochemical evidence that these aggregates are highly potent
in activating IRF3 in cytosolic extracts. Furthermore, the aggre-
gation of MAVS could be robustly induced in vitro by incubation
of mitochondria with RIG-I and K63 ubiquitin chains. Most
remarkably, our new data reveal that the CARD domains of458 Cell 146, 448–461, August 5, 2011 ª2011 Elsevier Inc.MAVS form protease-resistant prion-like fibrils, which effectively
convert endogenous MAVS on the mitochondria into functional
aggregates. Based on these results and other published data,
we propose a model of MAVS activation that involves the
following steps (Figure 7): (1) RIG-I binds to viral RNA through
the C-terminal RD domain and the helicase domain; (2) RIG-I
hydrolyzes ATP, undergoes a conformational change, and forms
a dimer that exposes the N-terminal CARD domains; (3) the
CARDdomains recruit TRIM25 and other ubiquitination enzymes
to synthesize unanchored K63 polyubiquitin chains, which bind
to the CARD domains; (4) the ubiquitin-bound CARD domains
of RIG-I interact with the CARD domain of MAVS, which is
anchored to the mitochondrial outer membrane through its
C-terminal TM domain; (5) the CARD domain of MAVS rapidly
forms prion-like aggregates, which convert other MAVS mole-
cules into aggregates in a highly processive manner; and (6)
the large MAVS aggregates interact with cytosolic signaling
proteins, such as TRAFs, resulting in the activation of IKK and
TBK1.
Prions are self-propagating protein aggregates that are best
known for causing fatal neurodegenerative diseases (Prusiner,
1998). However, accumulating evidence through studies in fungi
and other organisms suggests that prion-catalyzed conforma-
tional switches can regulate phenotypes in away that is not detri-
mental and is, in some cases, beneficial to a cell or organism
(Halfmann and Lindquist, 2010; Tuite and Serio, 2010). A recent
example of beneficial prions is provided by the invertebrate
Aplysia translation regulator CPEB, which forms self-sustaining
polymers that contribute to long-term facilitation in sensory
neurons (Si et al., 2003, 2010). Our finding that MAVS forms
highly active, self-perpetuating fiber-like polymers provides
another example of beneficial prions, in this case regulating
mammalian antiviral immune defense.
MAVS shares many hallmarks of a prion, including: (1) the
ability to ‘‘infect’’ the endogenous protein and convert it into
the aggregate forms; (2) the formation of fiber-like polymers; (3)
resistance to protease digestion; and (4) resistance to detergent
solubilization. Surprisingly, although endogenous MAVS aggre-
gates from virus-stimulated cells were resistant to 2% SDS as
analyzed by SDD-AGE, these aggregates were sensitive to treat-
ment with reducing agents such as DTT, suggesting disulfide
bond formation within functional MAVS aggregates. Interest-
ingly, disulfide bond formation has also been found in some
prions, such as PrP (Stanker et al., 2010). However, even after
DTT treatment, MAVS still sediments as very large and active
particles after sucrose gradient ultracentrifugation, suggesting
that disulfide bond formation is not essential to maintain the
aggregation and activity of MAVS.
It remains to be determined whether MAVS forms one or
a few very large aggregates or whether the aggregates are
broken down to smaller fragments, which then form new
‘‘seeds’’ to multiply the aggregates. It would also be inter-
esting to investigate how cells resolve these mitochondrial
aggregates after an immune response is called into motion.
Although there is evidence that MAVS is degraded by the
ubiquitin-proteasome pathway (You et al., 2009), other mech-
anisms such as mitophagy or chaperone-mediated refolding
are potentially involved in clearing the MAVS aggregates.
Interestingly, we found that geldanamycin and its analog 17-
AAG, which was previously known to inhibit IRF3 activation
by RNA viruses, block MAVS aggregation. The dose response
of the drugs shows an excellent correlation between MAVS
aggregation and IRF3 dimerization, suggesting that MAVS
aggregation is required for its function. It remains to be deter-
mined whether the effect of geldanamycin is due to its inhibi-
tion of Hsp90. It is possible that Hsp90 facilitates ordered
assembly of the functional MAVS fibers by preventing nonspe-
cific aggregation.
Many prions form amyloids consisting predominantly of
b sheets that may be detected with dyes such as Congo red
(Chien et al., 2004; Sawaya et al., 2007). However, we have
been unable to observe staining of MAVS aggregates with
Congo red (data not shown). Like the CARD domains of other
proteins, MAVS CARD forms a six-helix bundle (Potter et al.,
2008). Likewise, other priongenic proteins, such as the native
form of PrP (PrPc), form a-helical folds before they are converted
to the aggregate forms (Chien et al., 2004). Further studies arerequired to determine the atomic structure of the MAVS fibers
and to understand how the fiber structure gains the competence
to initiate downstream signaling. Importantly, MAVS fibers, but
not PrP fibers, are able to induce endogenous MAVS aggrega-
tion, indicating specificity in this conformation-based mecha-
nism of cell signaling.
CARD and CARD-like domains are present in a large variety of
proteins, especially those involved in immune defense and cell
death (Park et al., 2007). CARD domains are well known to
mediate protein-protein interactions, and the CARD domains of
RIG-I and MAVS likely mediate the interaction between these
proteins. Surprisingly, our studies reveal that the CARD domains
of RIG-I and MAVS have additional unique functions. The
tandem CARD domains of RIG-I, but not the MAVS CARD,
bind specifically to K63 polyubiquitin chains (Zeng et al.,
2010). On the other hand, the CARD domain of MAVS, but not
those of RIG-I, can form prion-like aggregates. The primary
sequences of the CARD domains of RIG-I, MDA5, and MAVS
are distantly related to conventional CARD domains found in
other proteins. Interestingly, whereas the CARD domain of
MAVS shares very limited sequence homology with those of
RIG-I and MDA5, the CARD domains of MAVS from different
species have high degrees of sequence homology, and both
mouse and human MAVS can form prion-like functional fibers
(Figure 3). Thus, the MAVS CARD domain may have evolved to
acquire the propensity to form prion-like aggregates, which
obviously benefit the host organisms by mounting rigorous anti-
viral immune defense.
In cells, the CARD domain of MAVS must be appended to the
mitochondrial targeting domain (TM) in order to induce IRF3
activation (Seth et al., 2005). In fact, overexpression of mini-
MAVS that contains only the CARD and TM domains is sufficient
to activate IRF3 and induce IFNb in cells (Seth et al., 2005)
(Figure S4F). The importance of the mitochondrial localization
of MAVS is underscored by the fact that hepatitis C virus
employs the viral protease NS3/4A to cleave MAVS off the mito-
chondrial membrane, thereby suppressing type I interferon
production (Li et al., 2005; Meylan et al., 2005). Surprisingly,
we found that recombinant MAVS lacking the TM domain
(MAVSDTM) could activate IRF3 when it is incubated with cyto-
solic extracts. Even a fragment containing only theCARDdomain
of MAVS is sufficient to form aggregates in vitro. The CARD
domain aggregates can also activate IRF3 in cytosolic extracts,
but in this case, the activity requires intact mitochondria contain-
ing endogenous MAVS (Figures 4D–4F). These biochemical
results are consistent with our new finding that the induction of
IFNb by mini-MAVS in cells requires endogenous MAVS (Fig-
ure S4F). Taken together, our results suggest that the CARD
domain of MAVSmediates aggregation, whereas the intervening
sequence between CARD and TM domains is important for
recruiting cytosolic signaling proteins to activate IKK and TBK1.
Though the vast majority of MAVS is located on the mitochon-
drial membrane, a very small fraction of MAVS is located on the
peroxisomal membrane (Dixit et al., 2010). When MAVS was
engineered to express predominantly on peroxisomal
membrane, it failed to induce type I interferons but could still
induce some antiviral genes, such as viperin, to inhibit viral infec-
tion through an interferon-independent mechanism. Our crudeCell 146, 448–461, August 5, 2011 ª2011 Elsevier Inc. 459
mitochondrial preparation likely contains peroxisomes, raising
the interesting possibility that a small fraction of MAVS that is
located on the peroxisomal membrane may also form aggre-
gates to induce viperin and other antiviral molecules.
Although overexpression ofMAVS in cells is sufficient to cause
its aggregation and induce type I interferons, the aggregation
and activation of endogenous MAVS is tightly regulated by viral
infection. We found that viral infection causes almost complete
conversion of endogenous full-length MAVS into the aggregate
forms. Such a highly efficient aggregation of MAVS can be repro-
duced in vitro by a simple incubation of mitochondria, RIG-I
CARD domains, and K63-Ub4. Moreover, endogenous MAVS
rapidly aggregates upon exposure of the mitochondria to the
fibers consisting of MAVS CARD domain. These results suggest
an amplification cascade in which the RIG-I:Ub chain complex
causes some MAVS molecules to form aggregates, which then
function as prion-like ‘‘seeds’’ to convert other MAVS molecules
to form aggregates. Indeed, we found that substoichiometric
amounts of K63-Ub4 and the MAVS CARD fibrils could cause
almost complete conversion of endogenous MAVS into func-
tional aggregates within 30 min in vitro, suggesting that the
RIG-I:Ub chain complex and MAVS fibrils function like catalysts.
This is consistent with our previous estimate that less than 20
molecules of viral RNA and K63 ubiquitin chains in a cell are suffi-
cient to cause detectable IRF3 activation (Zeng et al., 2010).
Thus, the RIG-I pathway appears to be highly sensitive to viral
infection. Our finding of the prion-like conformational switch of
MAVS provides a mechanism underlying this ultrasensitive and
robust antiviral response.
EXPERIMENTAL PROCEDURES
In Vitro IRF3 Activation Assay
Crudemitochondria (P5) and cytosolic extracts (S5) were prepared by differen-
tial centrifugation. In brief, HEK293T cells were resuspended in Buffer A
(10 mM Tris-HCl [pH 7.5], 10 mM KCl, 1.5 mM MgCl2, 0.25 M D-mannitol,
and Roche EDTA-free protease inhibitor cocktail) and then lysed by repeated
douncing. After removing the cell debris by centrifugation at 1000 3 g for
5 min, the supernatants were centrifuged at 10,000 3 g for 10 min at 4C to
separate P5 and S5. 35S-IRF3 was synthesized by in vitro translation in rabbit
reticulocyte lysates (TNT; Promega) using pcDNA3-Flag-IRF3 as the template.
P5 and S5 were incubated with 35S-IRF3 and ATP, and then IRF3 dimerization
was analyzed by native gel electrophoresis as described (Zeng et al., 2009).
Purification of Functional Flag-MAVS Particles from Virus-Infected
Cells
HEK293T cells stably expressing Flag-MAVS (human) were infected with Sen-
dai virus for 14 hr and then lysed in Buffer A by repeated douncing. After differ-
ential centrifugation as described above, mitochondria were further purified by
sucrose density ultracentrifugation. In brief, mitochondria resuspended in
Buffer B (20 mM HEPES [pH 7.4], 10% glycerol, 0.5mM EGTA, and 0.25 M
D-mannitol) were loaded on top of a centrifuge tube containing 1 ml of 50%
sucrose in phosphate-buffered saline (PBS) on the bottom layer and 1 ml of
40% sucrose in PBS on the top layer. After centrifugation at 100,000 3 g for
30 min, mitochondria enriched at the interface of two layers were collected
and solubilized with PBS containing 1% DDM. The mitochondrial lysate was
loaded onto a sucrose gradient (30%–60%) and centrifuged at 170,000 3 g
for 2 hr. Nine fractions with equal volume were taken from the top to bottom
of the tube. Fractions containing MAVS (corresponding to about 50%–60%
sucrose) were pooled, and then guanidine-HCl was added to 2.5 M. The
mixture was dialyzed against PBS containing 0.5 M Guanidine-HCl and
0.2%DDMovernight. Flag-MAVS was purified from the dialyzedmixture using460 Cell 146, 448–461, August 5, 2011 ª2011 Elsevier Inc.anti-Flag (M2) agarose beads and eluted with the Flag-peptide (200 mg/ml). All
procedures were performed at 4C.
Purification of Flag-MAVS from uninfected cells was carried out as above
except that, after isolation ofmitochondria by sucrose gradient ultracentrifuga-
tion, the mitochondrial lysate was loaded on top of 40% sucrose cushion and
centrifuged at 170,000 3 g for 2 hr. The fraction above the sucrose cushion
was incubated with anti-Flag (M2) agarose beads, followed by elution of
Flag-MAVS with the Flag peptide.
Expression, Purification, and Protease Digestion of Recombinant
MAVS Proteins
The bacterial expression vector pET-28a-His6-Sumo-MAVS or pET14b-
mMAVS was transformed into BL-21(pLys). Protein expression was induced
with 0.2 mM IPTG at 18C for 4 hr. After sonication in Buffer C (10 mM Tris-HCl
[pH 8.0], 500 mM NaCl, 5 mM b-mercaptoethanol, 0.5 mM DTT, 5% glycerol,
0.5mMPMSF, 0.5mMAEBSF, and 10mM imidazole), cell lysates were centri-
fuged at 50,000 3 g for 30 min. His6-Sumo-MAVS and His6-mMAVS in the
supernatant were purified using Ni-NTA beads, loaded onto a Hitrap-Q
column, and then eluted with Buffer D (10 mM Tris [pH 7.5], 5% glycerol,
2 mM DTT, 1 mM EDTA, 0.5 mM PMSF, and 0.5 mM AEBSF) containing
a gradient of NaCl from 0.1 M to 0.5 M. The fractions containing His6-Sumo-
MAVS, which was eluted with 300 mM NaCl, were pooled and loaded onto
a Superdex-200 gel filtration column equilibrated with Buffer E (10 mM
Tris-HCl [pH 8.0], 150 mM NaCl, 1 mM DTT, 1 mM EDTA, 0.5 mM PMSF,
and 0.5 mM AEBSF). FPLC (GE Healthcare) and a 24 ml Superdex-200 were
used for large-scale purification, whereas a SMART or ETTAN purification
system (GE Healthcare) and a 2.4 ml Superdex-200 column were used for
small-scale purification.
Purified His6-Sumo-MAVS was digested with proteinase K (mass ratio 50:1)
at room temperature (22C) for the indicated time. To isolate the protease-
resistant fragments, the reaction mixture was fractionated on Superdex-200
using the ETTAN system.
Flag-MAVS containing only the CARD domain was expressed in HEK293T
cells by transient transfection of pcDNA3-Flag-MAVS-CARD. At 48 hr after
transfection, cells were lysed in Buffer F (20 mM Tris-HCl [pH 8.0], 150 mM
NaCl, 10% glycerol, 0.1% Triton X-100, 1 mM DTT, and protease inhibitors).
After centrifugation at 10,0003 g for 10 min, Flag-MAVS CARD was absorbed
on anti-Flag agarose beads and eluted with the Flag peptide. The eluate was
further fractioned on Superdex-200 using the ETTAN system.
Semidenaturing Detergent Agarose Gel Electrophoresis
Semidenaturing detergent agarose gel electrophoresis (SDD-AGE) was per-
formed according to a published protocol with minor modifications (Alberti
et al., 2009). In brief, crude mitochondria (P5) were resuspended in 13 sample
buffer (0.5 3 TBE, 10% glycerol, 2% SDS, and 0.0025% bromophenol blue)
and loaded onto a vertical 1.5% agarose gel (Bio-Rad). After electrophoresis
in the running buffer (1 3 TBE and 0.1% SDS) for 35 min with a constant
voltage of 100 V at 4C, the proteins were transferred to Immobilon membrane
(Millipore) for immunoblotting.
Induction of Endogenous MAVS Aggregation and Activation In Vitro
Crudemitochondria (P5) were isolated fromHEK293T cells and incubated with
indicated amounts of RIG-I, ubiquitin chains, or recombinant MAVS proteins at
22C for different lengths of time. The reaction mixtures were centrifuged at
10,000 3 g for 10 min, and then the pellets were analyzed by SDD-AGE and
IRF3 dimerization assays. For ultracentrifugation analyses, the pellets were
resuspended in PBS containing 1% DDM, treated with or without 10 mM
DTT for 30 min, and then loaded on top of a sucrose gradient (20%–60%)
and centrifuged at 170,000 3 g for 2 hr.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
five figures and can be found with this article online at doi:10.1016/j.cell.
2011.06.041.
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